Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype 1b-infected patients undergoing combined treatment with PEG- or STD-IFN plus RBV

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 2, 2003, Pages 162-165

  Abbate, I ^a   Cappiello, G ^a   Lo Iacono, O ^b,c   Longo, R ^a   Ferraro, D ^c   Antonucci, G ^b   Di Marco, V ^c   Di Stefano, R ^c   Craxi, A ^c   Solmone, M C ^b   Spano A ^a   Ippolito, G ^b   Capobianchi, Maria Rosaria ^b  

^a SANDRO PERTINI HOSPITAL   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Genetic heterogeneity; HCV; PEG IFN; Quasispecies

Indexed keywords

ALPHA2B INTERFERON; GENE PRODUCT; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS ENVELOPE PROTEIN;

AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MOLECULAR EVOLUTION; NONHUMAN; OUTCOMES RESEARCH; PREDICTION; PROTEIN POLYMORPHISM; RELAPSE; SPECIES DIFFERENCE; STATISTICAL ANALYSIS; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 12444254807     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Fried MW. Advances in therapy for chronic hepatitis C. Clin Liver Dis 2001; 5: 1009-23.
2. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alpha-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-79.
3. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
4. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MMC. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-10.
5. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal trasduction through the Jak-STAT pathway. J Virol 1999; 73: 8469-75.
6. Gale M, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus non structural 5A protein: molecular mechanisms of kinase regulation. Molecular and Cellular Biology 1998; 18: 5208-18.
7. Enomoto N, Kurosaki M, Tanaka Y, Marumo F, Sato C. Fluctuation of hepatitis C virus quasispecies in persistent infection and interferon treatment revealed by single-strand conformation polymorphism analysis. J Gen Virol 1994; 75: 1361-9.
8. Manzin A, Solforosi L, Debiaggi, et al. Dominant role of host selective pressure in driving hepatitis C virus evolution in perinatal infection. J Virol 2000; 74: 4327-34.
9. Farci P, Shimoda A, Colana A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 399-44.
10. Farci P, Strazzera R, Alter HJ, et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci USA 2002; 99: 3081-6.
11. Polyak SJ, McArdle S, Liu SL, et al. Evolution of hepatitis C virus quasispecies in hypervariable region 1 and the putative interferon sensitivity-determining region during interferon therapy and natural infection. J Virol 1998; 72: 4288-96.
12. Pawlotsky JM, Germanidis G, Frainais PO, et al. Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol 1999; 73: 6490-9.
13. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334: 77-81.
14. Watanabe H, Enomoto N, Nagayama K, et al. Number and position of mutation in the Interferon (IFN) Sensivity-Determining Region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J Infect Dis 2001; 183: 1195-203.
15. Sandres K, Dubois M, Pasquier C, et al. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensivity of HCV to alpha interferon therapy. J Virol 2000; 74: 661-8.
16. Boulestin A, Sandres-Sauné K, Payen J, et al. Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon-α . J Med Virol 2002; 68: 221-8.
17. Yeh B, Han K, Lee H, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus type 1b infection. J Med Virol 2002; 66: 481-7.
18. Grahoovac Bingulac-Popovic J, Vucelic B, Hrstic I, et al. Hypervariable region 1 of hepatitic C virus genome and response to interferon therapy. Clin Chem Lab Med 2000; 38: 905-10.
19. Sookoian S, Castano G, Frider B, Cello J, Campos R, Flichman D. Combined therapy with interferon and ribavirin in chronic hepatitis C does not affect serum quasispecies diversity. Dig Dis Sci 2001; 46: 1067-71.